REScUE-OLE: An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study (clinicaltrials.gov) - Oct 14, 2026 - P3 | N=41 | Completed | Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Active, not recruiting ➔ Completed | N=108 ➔ 41
Enrollment change • Trial completion • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease
|